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Background
In immunocompetent individuals, infection with Parvovirus B 19 (B19V), a small, single stranded DNA virus, often remains asymptomatic but may also cause fever, maculopapular rash or arthralgia [1, 2] . In pregnancy B19V infection may lead to fetal transmission in approximately 30% of the cases and result in non-immune hydrops fetalis, fetal hepatitis, myocarditis and peritonitis [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] . Such severe complications predominantly occur in a "high risk window" of up to 20 weeks after acute B19V infection, calling for an accurate virological diagnosis of B19V infection [6, 9, 12, 13] .
Diagnosis of acute B19V infection is typically based on the detection of anti-B19V
IgM and/or seroconversion of IgG using enzyme linked immunosorbent assays (ELISA) as wells as on the detection of viral DNA by nucleic acid-based polymerase chain reaction (PCR) [6, [14] [15] [16] [17] [18] [19] . In certain immunocompetent individuals, however, B19V DNA may remain persistently detectable in the blood for months or even years after infection [9, [20] [21] [22] . The possibility of such prolonged B19V DNAemia as well as IgM persistence or unspecific ELISA reactivity make it difficult to evaluate the exact time point of infection and require the use of additional virological methods [16, 23] .
Numerous studies have demonstrated that measurement of the binding avidity or the epitope-type specificity (ETS) or conformation dependence of anti-B19V IgG antibodies improved staging of B19V infection [6, 16, [24] [25] [26] [27] . Results obtained by these serological assays were also compared to B19V PCR measurements, and it was shown that significantly higher B19V DNA loads can be detected in patients with a serological profile of recent infection [26] .
With the aim to identify an additional marker that is able to discriminate between acute and past infection in patients with B19V DNAemia, we now comprehensively analyzed patients with B19V DNAemia for viral DNA loads, anti-B19V IgM and IgG, anti-VP1 IgG avidity, anti-VP-2 ETS and included CXC-ligand 10 (CXCL-10, Interferon-inducible protein A c c e p t e d M a n u s c r i p t -6 -of 10 kilodaltons, IP-10) in this analysis. CXCL-10 is a CXCR3-binding chemokine that is secreted by infected cells and attracts immune cells with a cytokine profile of T-helper cells Type 1 (Th1) to the site of the infection [28] [29] [30] [31] [32] . The rationale for choosing CXCL-10 as a marker was based on previous studies with Human Immunodeficiency Virus (HIV), Human
Cytomegalovirus and Hepatitis C Virus (HCV), showing that CXCL-10 may serve as clinical indicator for the clinical disease severity, progression and antiviral therapy outcome [33] [34] [35] [36] [37] [38] [39] .
Methods

Patients and samples
This retrospective study included B19V DNA positive serum samples acquired due to virological diagnosis between January 2004 and January 2015 from 222 immunocompetent individuals (178 female, including 127 pregnant women, and 44 male) with a mean age of 31 years (range 3-78). The patients were investigated for B19V because they displayed typical symptoms for B19V infection (fever, a typical maculopapular rash ± arthralgia; n=98 patients) or there was exposure to B19V (n=120 individuals including 77 pregnant women) or fetal abnormalities were detected during pregnancy (n=4). The study also included samples from 14 healthy controls with no evidence of B19V or any other infection. Patients and controls denied presence of immunologic and oncologic disorders and intake of immunosuppressive medication. In physical examination patients displayed no symptoms other than those related to B19V infection.
The study protocol was approved by the ethics committee of the Medical University of Vienna (EK1582/2015). Since the samples had been acquired for virological diagnosis and in the distant past, the local ethics committee concluded that no written informed consent from the patients was required (EK1035/2016).
A c c e p t e d M a n u s c r i p t -7 -Detection of B19V DNA B19V DNA was quantitatively assessed using a TaqMan®-based B19V real-time PCR. In brief, 5µl of DNA, extracted using NucliSENS® easyMag® technology, (bioMerieux, Marcy l'Etoile, France), were added to the amplification mixture using TaqMan® universal PCR master mix (Applied Biosystems®, Foster City, CA, USA) and yielding a total volume of 25 µl. The cycling conditions were 3 min at 50°C, 10 min at 95°C followed by 45 cycles of 95°C for 15 sec, 55°C and 72°C each for 30 sec. The Parvovirus B19 primers and probe are located in the VP2 gene as described previously [19] .
Serology
B19V specific IgM and IgG
Commercial B19V-specific IgM and IgG ELISAs were performed according to the manufacturer´s instructions (Parvo B19 IgM-ELISA and Parvo B19 IgG-ELISA, Medac, Wedel, Germany). In-house anti-B19V VP2 IgM and IgG ELISA assays were performed at the Department of Virology in Helsinki, as described previously [26] . In brief, Microtiter plate wells (Costar, Corning, NY, USA) were coated with goat anti-human IgM or IgG (Cappel/ICN Biomedicals, Costa Mesa, CA, USA). After blocking, wells were incubated with diluted serum samples and washed with PBS. Then biotinylated insect cell-produced B19V VP2 virus-like particles were added. After incubation and washing, peroxidase conjugated streptavidin (P0397; Dako, Glostrup, Denmark) was added. After another cycle of incubation and washing, o-phenylenediamine dihydrochloride (S2045; Dako) and H2O2 was added for visualization, which was read at 492 nm using a spectrophotometer (Labsystems Multiscan EX; Thermo Fisher, Helsinki, Finland).
A c c e p t e d M a n u s c r i p t -8 -VP1 IgG avidity and VP2 IgG epitope type specificity VP1 IgG avidity was measured as described [26] . In brief, wells coated with the recombinant protein of the VP1 unique region, together with a short segment of the VP1-VP2 shared sequence, were incubated with patient sera, prepared in two dilution series per serum sample. One series was washed with 8M urea and the other with PBS. After adding Antihuman IgG-horseradish peroxidase conjugate (DakoCytomation), incubation and multiple washing steps, antibody binding was visualized by addition of orthophenylene diamine substrate. The ratio of IgG titers, with and without urea treatment was calculated using curve-fitting software. In these avidity indices the cutoff values for low and high avidity were 15% and 25%, respectively [26] .
The VP2 IgG ETS ELISA was performed as described [27] . In brief, IgG reactivity was measured using as antigens baculovirus-expressed VP2 capsids and a synthetic 
CXCL-10 Measurement
CXCL-10 serum levels were quantitated using a commercially available ELISA (BD OPTEIA Human IP-10 ELISA Set, Becton Dickinson Biosciences, San Diego, CA, USA) using a modified protocol [33, 34] . The lower limit of detection was 7.5 picograms (pg) per ml. Each sample was tested undiluted and in 10-fold dilution. As described previously, the relationship between CXCL-10 measurements in diluted and undiluted samples was not linear, but piecewise linear, with the degree of divergence increasing with increasing concentration. Therefore, the cutoff points for the pieces of linearity were determined, and A c c e p t e d M a n u s c r i p t -9 -the concentration in undiluted samples with CXCL-10 levels was estimated from the reverse function [33, 34] .
Statistical methods
Intra-individual CXCL-10 kinetics was analyzed using paired nonparametric t-tests 
Results
Anti-B19V serology in individuals with B19V DNAemia
Samples from 222 individuals with B19V DNAemia were tested for anti-B19V IgM and IgG using ELISA. The results are presented in Table 1 [26, 27] . On the other hand, avidity or ETS yielded results of past infection in 95% of 76 individuals with detectable IgG but undetectable IgM antibodies (Table 1) .
CXCL-10 increases due to acute B19V infection
In order to analyze whether acute B19V infection caused a change of CXCL-10 serum levels from uninfected baseline, we first examined CXCL-10 responses in small cohort of 12 pregnant women. In these patients, in addition to samples acquired during acute B19V infection, serum samples were available that were collected before the infection with a median interval of 50 days (range: 19-180). In each of the patients the CXCL-10 level in this uninfected baseline sample, which was highly similar to CXCL-10 levels in healthy uninfected controls, was then compared to the level detected when acute B19V infection was diagnosed (defined as detection of B19V DNA, B19V-specific IgM and IgG with low avidity and IgG seroconversion). As shown in Figure 1 , there was a significant increase of serum CXCL-10 levels from baseline due to acute B19V infection (p=0.0005, Wilcoxon matched pairs test). In each case, the CXCL-10 level in acute B19V infection was higher than a cutoff determined in healthy uninfected controls (mean + 3x standard deviation; 92.43pg/ml).
CXCL-10 in sequential stages of B19V infection
In 17 patients multiple serum samples were available obtained at sequential time points, and in these patients intra-individual CXCL-10 kinetics during B19V infection could be investigated. As shown in Figure 2A , CXCL-10 levels peaked in these patients during the acute phase of B19V infection (p<0.05, Friedman test). Also in a patient, in whom B19V DNA remained detectable during an observational period of 6 years, CXCL-10 levels peaked We also analyzed CXCL-10 levels in relation to data obtained by avidity testing. For this purpose we correlated CXC-10 levels with the avidity in all patients, of whom at least one B19V IgG positive sample was available [26] . As shown in Figure 3 , there was a significant inverse correlation between the CXCL-10 level and VP1u-IgG avidity (p<0.0001, r=-0.5785, Spearman correlation, Figure 4 ).
CXCL-10 as a marker of B19V infection stage
Finally, we assessed the ability of CXCL-10 serum levels to differentiate between acute and past B19V infection. To this end we performed a ROC analysis with the two groups of patients with B19V DNAemia, in whom the combination of all serological data unequivocally indicated either acute or past infection (acute: n=108, past infection: n=63).
Acute infection was defined by (i) undetectable anti-B19V IgM and IgG, (ii) detectable IgM but undetectable IgG or (iii) detectable IgM and IgG (commercial and in-house assays, respectively) in the presence of low IgG avidity plus an ETS ratio ≤20. Past infection was
A c c e p t e d M a n u s c r i p t -12 -defined by undetectable IgM, detectable IgG (commercial and in-house assays, respectively) in the presence of high anti-B19V IgG avidity plus an ETS ratio >20 [26, 27] .
The ROC analysis revealed that acute and past infection could be distinguished based on CXCL-10 levels, with an area under the curve (AUC) of 0.9047 (p<0.0001, Figure 4A) . Also, the B19V DNA loads in serum significantly differed between patients with acute and past infection (AUC=0.9708, p<0.0001; Figure 4B ).
Furthermore, when the combination of CXCL-10 and B19V DNA levels was used as a marker (with optimal cut-offs evaluated in ROC analyses), there was a highly significant association of double-positivity with acute and double-negativity with past infection, respectively (Fisher´s exact test, p<0.0001, Figure 4C ). Of note, there was a high discriminatory power for acute and past infection when CXCL-10 and B19V DNA were used in combination, and this power was higher than those of the sole markers ( Table 2) .
Discussion
Results from this study demonstrate that acute B19V infection is associated with an increase of the chemokine CXCL-10 and that CXCL-10 serum levels can be used as marker to distinguish between acute and past infection in immunocompetent individuals with B19V DNAemia.
Since B19V DNA may remain detectable for many months or even years, while B19V associated complications in the fetus predominantly occur due to maternal infection in the first half of pregnancy and during the first months post-infection, it is imperative to know, when B19V DNAemia is detected, whether it originates from acute or past infection [6, 9, 12, 13] . In the present study we analyzed the ability of CXCL-10 levels as a marker for acute infection using as a reference a comprehensive panel of serological and molecular approaches. We detected elevated serum levels of CXCL-10 in all patients with active B19V infection, and especially in those with acute or recent infection. Moreover, in agreement with A c c e p t e d M a n u s c r i p t -13 -a previous study, we found significantly higher B19V DNA loads in patients with acute onset of B19V infection [26] . Since we demonstrated an excellent discriminatory ability to distinguish between acute and past B19V infection when CXCL-10 and B19V DNA were used as combined indicators, we propose that CXCL-10 serum levels could significantly contribute to the confirmation or exclusion of acute B19V infection in immunocompetent individuals with B19V DNAemia. However, since CXCL-10 production is part of the innate response and not specific for B19V, high CXCL-10 should only be interpreted as sole indicator for acute B19V infection, when there is no evidence for any coinfections.
Furthermore, based on variations in individual CXCL-10 levels during acute B19V infection, testing of a second serum sample should be considered, especially when CXCL-10 levels slightly exceed the cutoff level.
The simultaneous presence of the CXCL-10 and B19V DNA in blood, which we here first showed, additionally provides some interesting points for discussion. In other viral infections CXCL-10 has been shown to be essential for an efficient antiviral immune response by attraction of T-cells with a Th1 cytokine profile to the site of viral replication and the same could apply for B19V infection [40, 41] . Our observation that CXCL-10 levels increase and significantly peak in acute B19V infection corresponds to previous findings with HIV and HCV, which induce a prompt CXCL-10 increase immediately after the infection, and points to a functional link between bone marrow erythroid progenitor cell derived B19V and CXCL-10 production [33, 34, 42, 43] .
Previous findings indicate that B19V DNA may remain detectable in the blood for a prolonged period of time, and we also made this observation in an immunocompetent individual (Supplemental Figure 1) [16, [20] [21] [22] 44] . However, we additionally demonstrated that individuals with B19V DNAemia, even when their serological profile indicated past infection, showed higher CXCL-10 serum levels than uninfected controls. This opens the question, whether increased CXCL-10 production, which is apparently linked to prolonged interestingly indicated that increased levels of Th1 associated cytokines in convalescent B19V infection might be associated with prolonged fatigue [45] . Of note, increased CXCL-10 levels also occur in different autoimmune disorders for which B19V has been suspected as causative agent [46] [47] [48] . Increased CXCL-10 levels, produced upon B19V replication, might, e.g. in post-infectious arthropathy, trigger T-cell attraction and enhanced inflammation in the affected tissue, yet this calls for further investigation [49] .
Our data overall demonstrate that productive B19V infection is closely associated with a CXCL-10 response, and that CXCL-10 serum levels might serve as a diagnostic marker to discriminate between recent and past B19V exposure in immunocompetent individuals with B19V DNAemia. M a n u s c r i p t M a n u s c r i p t A c c e p t e d M a n u s c r i p t 
